Treatment of hepatitis C in solid organ transplantation

Drugs

Volumn 64, Issue 5, 2004, Pages 489-498

  Chan, Susan E ^a,b   Schwartz, Jonathan M ^a,b   Rosen, Hugo R ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

CLINICAL TRIAL; GRAFT REJECTION; HEMODIALYSIS; HEPATITIS C; HUMAN; LIVER INJURY; MORBIDITY; MORTALITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PREVALENCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; PREMEDICATION;

HEPATITIS C VIRUS;

EID: 1542721929     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464050-00003     Document Type: Review

References (79)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62
2. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
4. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43
5. Hinrichsen H, Leimenstoll G, Stegen G, et al. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-33
6. Rosen HR, Friedman L, Martin P. Hepatitis C and the renal transplant patient. Semin Dial 1996; 9: 39-47
7. Jadoul M, Cornu C, van Ypersele de Stirhou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-5
8. Genesca J, Vila J, Cordoba J, et al. Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. J Hepatol 1995; 22: 272-7
9. Willems M, Moshage H, Nevens F, et al. Plasma collected from heparinized blood is not suitable for HCV-RNA detection by conventional RT-PCR assay. J Virol Methods 1993; 42: 127-30
10. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999; 94: 3576-82
11. Cotler SJ, Diaz G, Gundlapalli S, et al. Characteristics of hepatitis C in renal transplant candidates. J Clin Gastroenterol 2002; 35: 191-5
12. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9
13. Kokado Y, Takahara S, Ichimaru N, et al. Clinical outcome of HCV infection after renal transplantation. Transplant Proc 2000; 32: 1940-3
14. Mas V, Alvarellos T, Chiurchiu C, et al. Hepatitis C virus infection after renal transplantation: viral load and outcome. Transplant Proc 2001; 33: 1791-3
15. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63
16. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alpha IFN-2B in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8
17. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23
18. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7
19. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001; 55: 220-6
20. Huraib S, Iqbal A, Tanimu D, et al. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435-40
21. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120-6
22. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001; 16: 1017-23
23. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha (2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-9
24. Benci A, Caremani M, Menchetti D, et al. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 141-4
25. Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414-9
26. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997; 176: 1614-7
27. Fernandez JL, Rendo P, del Pino N, et al. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels: Nephrologists' Group for the Study of HCV infection. J Viral Hepat 1997; 4: 113-9
28. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8
29. Raptopoulou-Gigi M, Spaia S, Garifallos A, et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1834-7
30. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507-9
31. Morales JM, Campistol JM. Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000; 11: 1343-53
32. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
33. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10
34. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-5
35. Gupta SK, Pittenger AL, Swan SK, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha 2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002; 42: 1109-15
36. Takahara S, Kakimoto K, Kokado Y, et al. Interferon alpha therapy for chronic active hepatitis type C after renal transplantation and allograft rejection. Int Urol Nephrol 1995; 27: 479-85
37. Durlik M, Gaciong Z, Rowinska D, et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 Suppl. 1: S135-9
38. Rostaing L, Izopet J, Baron E, et al. Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 1995; 10 Suppl. 6: 93-6
39. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10
40. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002; 74: 427-37
41. International Classification of Diseases. 9th rev. Geneva: World Health Organization, 1977
42. Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001; 71: 1189-204
43. Pereira BJ, Milford EL, Kirkman RL, et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med 1992; 327: 910-5
44. Pereira BJ, Wright TL, Schmid CH, et al. A controlled study of hepatitis C transmission by organ transplantation: the New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-7
45. Pfau PR, Rho R, DeNofrio D, et al. Hepatitis C transmission and infection by orthotopic heart transplantation. J Heart Lung Transplant 2000; 19: 350-4
46. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30: 1293-8
47. Zein NN, McGreger CG, Wendt NK, et al. Prevalence and outcome of hepatitis C infection among heart transplant recipients. J Heart Lung Transplant 1995; 14: 865-9
48. Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119: 1064-74
49. Castella M, Tenderich G, Koerner MM, et al. Outcome of heart transplantation in patients previously infected with hepatitis C virus. J Heart Lung Transplant 2001; 20: 595-8
50. Lake KD, Smith CI, Milfred-La Forest SK, et al. Outcomes of hepatitis C positive (HCV+) heart transplant recipients. Transplant Proc 1997; 29: 581-2
51. Lake KD, Smith CI, LaForest SK, et al. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant 1997; 16: 917-21
52. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44
53. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
54. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
55. Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: a survey of practices. J Heart Lung Transplant 1999; 18: 456-9
56. Fukumoto T, Berg T, Ku Y, et al. 1996 Viral Dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24: 1351-4
57. Forman LM, Lucey MR. Orthotopic liver transplantation for hepatitis C: analysis of allograft survival using the UNOS database [abstract no. 82]. Am J Transplant 2001; 1 Suppl. 1: 156
58. Gane EJ, Portmann BC, Naoumouv NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 821-7
59. Berenguer M, Ferell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84
60. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852-8
61. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72
62. Gretch DR, Bacchi CE, Corey L, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995; 22: 1-9
63. Gane EJ, Naoumov NV, Qian K-P, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77
64. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30
65. Charlton M. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl 2002; 8: S50-4
66. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8
67. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 82-6
68. Mazzaferro V, Tagger A, Schiavo M, et al. Prevalence of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-7
69. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-5
70. Everson GT, Trotter J, Kugelmas M. Long-term outcome of patients with chronic hepatitis C and decompensated liver disease treated with the LADR protocol (low-accelerating-dose regimen) [abstract]. Hepatology 2002; 36 (2): 297A
71. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002; 8: 449-57
72. Gane E. Treatment of recurrent hepatitis C. Liver Transpl 2002; 8: S28-37
73. Jain AB, Eghtesad B, Venkataramanan R, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8: 1007-13
74. Gopal D, Rabkin JM, Berk B, et al. Treatment of progressive HCV recurrence following liver transplatation with combination interferon and ribavirin therapy. Liver Transpl 2001; 7: 181-90
75. de Vera ME, Smallwood GA, Rosado K, et al. Interferon-a and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71: 678-86
76. Narayanan Menon KV, Poterucha JJ, El-Amín OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623-9
77. Riely C, Ferenci P, Peck-Radosavljevic M, et al. Pegylated (40 kDa) interferon alfa-2A (pegysus) in post-liver transplant recipients with established recurrent hepatitis C: a preliminary report [abstract 89]. Am J Transplantation 2001; 1 Suppl. 1: 158
78. Lavezzo B, Franchello AA, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247-52
79. Gopal DV, Rosen HR. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9: 348-53